



Market Announcement

12 June 2020

Race Oncology Ltd (ASX: RAC) – Trading Halt

Description

The securities of Race Oncology Ltd ('RAC') will be placed in trading halt at the request of RAC, pending it releasing an announcement. Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of the commencement of normal trading on Tuesday, 16 June 2020 or when the announcement is released to the market.

Issued by

Sean Maloney

Adviser, Listings Compliance (Perth)



12 June 2020

Listings Compliance (Perth)
ASX Compliance Pty Ltd
Level 40 Central Park
152-158 St George's Terrace
PERTH WA 6000

Via Email:

TradingHaltsPerth@asx.com.au

Dear Sir/Madam

TRADING HALT REQUEST

In accordance with ASX Listing Rule 17.1, Race Oncology Limited (the Company) hereby requests that its securities be placed into an immediate trading halt.

For the purposes of Listing Rule 17.1, the Company provides the following information:

- (a) the trading halt is requested pending an announcement regarding the release of results from the clinical trial conducted at Sheba Medical Centre, Tel Aviv, Israel;
- (b) the Company requests that the trading halt remain in place until the earlier of the Company making an announcement in relation to the release of results from the clinical trial conducted at Sheba Medical Centre, Tel Aviv, Israel, or until the market opens on Tuesday, 16 June 2020; and
- (c) the Company is not aware of any reason why the trading halt should not be granted.

Authorised for release by the Executive Chairman.

Dr John Cullity

Executive Chairman

john@biosynergypartners.com